| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2001;72:386-390
© 2001 The Society of Thoracic Surgeons
a Department of Surgery, The Montreal General Hospital, McGill University, Montreal, Quebec, Canada
b Department of Pathology, The Montreal General Hospital, McGill University, Montreal, Quebec, Canada
c SmithKline Beecham, King of Prussia, Pennsylvania, USA
Address reprint requests to Dr Giaid, The Montreal General Hospital, 1650 Cedar Ave, Suite L3-314, Montreal, PQ H3G 1A4, Canada
e-mail: adel.giaid{at}mcgill.ca
Presented at the Poster Session of the Thirty-sixth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 31–Feb 2, 2000.
Background. It is postulated that apoptosis contributes to ischemia-reperfusion graft dysfunction after lung transplantation. The purpose of this study was to determine whether the improvement in lung function that we previously observed with the use of an endothelin-1 (ET-1) receptor antagonist after ischemia-reperfusion injury is associated with a reduction in inducible nitric oxide synthase (NOSII) expression and programmed cell death.
Methods. Left lung canine allotransplantation was performed. Harvested lung blocks were preserved with modified Eurocollins solution and stored at 4°C for 18 to 20 hours. Lung allografts were tested for the expression of NOSII by immunohistochemistry, and extent of apoptosis by terminal dUTP nick end-labeling (TUNEL). Animals blindly received either an intravenous infusion of saline (control) or the ET-1 receptor antagonist (SB209670) (15 µg/kg/min). Infusion began 30 minutes pretransplantation and continued to 6 hours posttransplantation.
Results. Immunohistochemical analysis demonstrated significantly stronger NOSII immunostaining in the allografts of the saline control group (36.5% ± 3.6%) compared with native right lungs (6.9% ± 1.3%, p < 0.001) or the ET-receptor antagonist treatment group (9.6% ± 1.4%, p < 0.001). The TUNEL staining revealed a significantly stronger labeling in the allografts of the saline treatment control group (40.7% ± 6.2%) compared with native right lungs (5.0% ± 0.6%, p < 0.005) or the ET receptor antagonist treatment group (14.1% ± 2.8%, p < 0.01).
Conclusions. We conclude that treatment of lung allografts with the ET-1 receptor antagonist SB209670 reduces the area of NOSII expression and the extent of apoptosis, factors known to contribute to the process of prolonged ischemia-reperfusion injury.
This article has been cited by other articles:
|
|
 |
|
  K. Nowak, S. Weih, R. Metzger, R. F. Albrecht II, S. Post, P. Hohenberger, M.-M. Gebhard, and S. M. Danilov Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L162 - L169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Reece, V. E. Laubach, C. G. Tribble, T. S. Maxey, P. I. Ellman, P. S. Warren, A. M. Schulman, J. Linden, J. A. Kern, and I. L. Kron Adenosine A2A Receptor Agonist Improves Cardiac Dysfunction From Pulmonary Ischemia-Reperfusion Injury Ann. Thorac. Surg., April 1, 2005; 79(4): 1189 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Perrot and S. Keshavjee Lung preservation Ann. Thorac. Surg., August 1, 2002; 74(2): 629 - 631. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Karamsetty and J. R. Klinger NO: More Than Just a Vasodilator in Lung Transplantation Am. J. Respir. Cell Mol. Biol., January 1, 2002; 26(1): 1 - 5. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
